RELMADA THERAPEUTICS INC
RLMDNASDAQTrading Snapshot
- Day Range
- $3.69 – $3.78
- 52-Week Range
- $1.80 – $8.00
- Volume
- $2.95B
- Avg Volume
- $3.35B
- Shares Outstanding
- 104.9M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $38M
- Last Q Revenue
- $10M
- P/E Ratio
- -4.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.55
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +126.2%
Why Investors Own RLMD
- ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
RELMADA THERAPEUTICS INC
RLMD
StockOtter · stockotter.spaceAbout RELMADA THERAPEUTICS INC
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE
Bank of America Corp DE acquired a new stake in Relmada Therapeutics, Inc. (NASDAQ: RLMD) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 8
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street a
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could le